Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Elanco Animal Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Elanco Animal Health's regulatory disclosures and financial reporting.
Elanco Animal Health Inc (ELAN) reported that Executive Vice President U.S. Pet Health and Global Digital Transformation Rajeev A. Modi acquired 61.6158 Deferred Stock Units on 2026-08-21 as a grant or award. Each unit corresponds to one share of common stock or the cash equivalent and will settle in cash or shares after employment ends or in a specified future year under the Executive Deferral and Stock Match Plan. Following this award, Modi holds a total of 9,770.3122 Deferred Stock Units directly.
Elanco Animal Health Inc (ELAN) reported that EVP and CFO Robert M. VanHimbergen acquired 8.2194 Deferred Stock Units on 2026-08-21 as a grant/award. Each unit corresponds to one share of common stock or the cash equivalent and will settle in cash or shares after employment ends or in a specified future year. Following this award, he directly holds 141.8242 Deferred Stock Units.
Elanco Animal Health Inc (symbol: ELAN) is the issuer of record for a Form 4 filing submitted to the SEC.
Elanco Animal Health Inc (ELAN) director Lawrence Erik Kurzius reported an open-market purchase of 40,000 shares of common stock on August 20, 2026 at a weighted average price of $23.398 per share, with individual trades ranging from $23.385 to $23.40. Following these purchases, his reported direct holdings increased to 188,647 shares of Elanco common stock.
Elanco Animal Health Inc (ELAN) reported that officer Shiv O'Neill, General Counsel and Corporate Secretary, purchased 3,998 shares of common stock on 2026-08-18 at $23.58 per share in an open-market or private transaction. After this trade, O'Neill directly holds 87,832 shares of Elanco common stock. The transaction was not made pursuant to a Rule 10b5-1 trading plan.
Elanco Animal Health Inc director Michael J. Harrington purchased 5,000 shares of common stock on 2026-08-12 in an open market or private transaction at a price of $21.82 per share. Following this transaction, his directly held position increased to 131,451 shares of Elanco common stock.
Simmons Jeffrey N reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc reported that President, CEO and Director Jeffrey N. Simmons received a grant of 127.7997 Deferred Stock Units on 2026-08-07 at a reference value of $22.12 per unit. Each deferred stock unit represents the right to receive one share of common stock or the cash equivalent and will settle in cash or shares following termination of employment or in a specified future year under the Executive Deferral and Stock Match Plan. Following this award, Simmons holds 25,012.1875 Deferred Stock Units directly.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen reported two transactions on August 7, 2026. He received a grant of 8.9069 Deferred Stock Units, each representing the right to one share of common stock or cash, bringing his Deferred Stock Unit balance to 133.6048. On the same date, he purchased 4,200 shares of common stock in multiple transactions at a weighted average price of $23.0776 per share, with individual prices ranging from $23.01 to $23.09. Following these purchases, he directly owns 137,516 shares of Elanco Animal Health common stock.
Modi Rajeev A. reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc reported that Executive Vice President U.S. Pet Health and Global Digital Transformation Rajeev A. Modi received a grant of 66.7690 Deferred Stock Units tied to Company common stock at a reference price of $22.1200 per unit. Each unit represents the right to receive one share of common stock or the cash equivalent, settling in cash or shares after termination of employment or in a specified future year under the Executive Deferral and Stock Match Plan. Following this award, Modi holds a total of 9708.6964 Deferred Stock Units directly.
Elanco Animal Health Inc director Paul Herendeen reported an open-market purchase of 10,000 shares of Common Stock on August 7, 2026 at $23.685 per share. Following this transaction, his reported direct ownership increased to 111,687 common shares of Elanco Animal Health Inc.